Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

European funding plan 'unviable'

Top universities shun Joint Technology Initiatives.

The credibility of the European Commission's initiative to promote research collaborations between academia and industry is under threat because universities cannot afford to take part.

The Commission is setting up six public–private partnerships — known as Joint Technology Initiatives, or JTIs — that will undertake applied research under the European Union's €50-billion (US$63 billion) Seventh Framework Programme (FP7), which runs until 2013. Roughly half of the money for the JTIs comes from European Union funds, with €3.17 billion paid by member states as part of their contribution to FP7. Industry matches the contribution in kind by offering researchers, lab space and equipment.

But some of Europe's top universities say the terms of the JTIs make it too costly for them to take part. One of the main concerns is that universities can claim only 20% of the indirect costs of these research projects — including infrastructure, computing support and administrative services — from any of the JTI grants. By contrast, other FP7 projects reimburse universities with up to 60% of their indirect costs.

The University of Oxford, UK, has expressed an interest in five projects in the Innovative Medicines Initiative (IMI), which aims to speed up the drug-development process and will receive €1 billion in public funds between now and 2017. But Linda Polik, European adviser at Oxford's research services unit, says the university may have to pull out because it cannot afford to take part. "Even before the economic downturn we were not in a position to subsidize research to this extent. It is not financially viable to participate in the IMI."

Credit: SOURCE: EUROPEAN COMMISSION

The university complained to the Commission in September, but Polik says that the reply — from European research commissioner Janez Potočnik, who has personally backed the JTI scheme — failed to address their concerns.

University College London has expressed interest in only one IMI research project because the conditions are so unfavourable, says Michael Browne, the university's head of European research and development. "I am not going to be shouting from the rooftops to get our researchers involved in these," he says, adding that the schemes "will definitely fail without university participation".

Herbert Müther, vice-dean for research at the University of Tübingen in Germany, adds that the JTIs have failed to overcome the difficulties of getting universities to collaborate with industry, such as the different styles of conducting and communicating research, and disagreements over intellectual property rights.

The European Association of Research and Technology Organisations (EARTO), which represents public and private research bodies, warns that universities and smaller businesses could "turn their backs on JTIs — as many of them did during the first IMI call for proposals — if the conditions offered are not realistic".

Many research-policy experts contacted by Nature expressed the view that the JTIs are being used to subsidize industry, giving them substantial control over the intellectual property generated by the research. The Commission and industry partners involved in the IMI have agreed to set up a working group early next year to discuss the universities' concerns about these rules.

A spokesman for the European Federation of Pharmaceutical Industries and Associations in Brussels — which has five member companies on the IMI's governing board — says it is pleased with how the IMI is progressing, as it proves that industry and academic institutions can work together. The Commission says the decision to place a 20% cap on overhead costs is "a clear decision to focus as much of the funds as possible on research".

"The idea is to get research results to be applied quickly, which requires different rules to those adopted in the rest of FP7," a spokesman says. He adds that the Commission was "satisfied" with levels of interest in the IMI's first call for proposals, which saw 138 submissions. "That strikes me as quite underwhelming," says Christopher Hull, secretary general of EARTO.

Authors

Related links

Related links

Related external links

JTIs home page

EU Council decision on FP7 budget (pdf)

IMI update report November 2008 (pdf)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gilbert, N. European funding plan 'unviable'. Nature 456, 551 (2008). https://doi.org/10.1038/456551a

Download citation

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing